Wilson Therapeutics Appoints Chair
This article was originally published in Scrip
Wilson Therapeutics AB., a privately held pharmaceutical company, has appointed Andrew Kay chair of its board of directors. Hugh Rienoff, the company's previous chair, will continue to advise the company as a consultant. Kay is currently advisor and chair to various biotech companies and most recently was CEO of Algeta, a publicly traded oncology company acquired by Bayer. He was previously global head of marketing and sales at Novartis, vice-president of marketing US at Zeneca and also held commercial positions in Europe with AstraZeneca, Eli Lilly, Sandoz and Boots.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.